Quick Answer
Emergent BioSolutions Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $742.90 million for the year ending 2025.
- Emergent BioSolutions Inc. showed a decrease of -28.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Emergent BioSolutions Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2016 to 2025), Emergent BioSolutions Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 52.0%.
- Historical annual values: Fiscal year 2025: $742.90 million | Fiscal year 2024: $1.04 billion | Fiscal year 2023: $1.05 billion | Fiscal year 2020: $1.56 billion | Fiscal year 2019: $1.11 billion | Fiscal year 2018: $782.40 million | Fiscal year 2017: $560.90 million | Fiscal year 2016: $488.80 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: